NCT02941679Unknown3 期
A 24-week, Randomized, Double-Blind, Active-controlled, Parallel Study of HCP1202 Combination Product, HGP1011, and HCP0910 in Treatment of Subjects With COPD
Hanmi Pharmaceutical Company Limited0 个研究点目标入组 252 人开始时间: 2016年10月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 发起方
- 入组人数
- 252
- 主要终点
- Change from Baseline in Trough FEV1 at Week 12
研究概览
简要总结
A phase 3 study to evaluate efficacy and safety of HCP1202
详细描述
This study is designed as a multi-center, double-blinded, randomized, phase 3 clinical trial to evaluate the efficacy and safety of HCP1202 compared to either treatment with HGP1011 or HCP0910 in COPD patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 40 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or Female adults aged ≥ 40 years.
- •Patients diagnosed with COPD.
- •Patients with FEV1/FVC < 0.7 at screening.
- •Patients with a post-bronchodilator FEV1 < 60% of the predicted normal OR Patients with a post-bronchodilator FEV1 < 80% of the predicted normal if COPD exacerbation is moderate or worse developed at least twice within the past year or hospitalization occurred at least once within the past year due to COPD exacerbation.
- •Patients with COPD Assessment Test ≥
- •Patients with a history (current or ex-smokers) of smoking 10 pack-years or more (e.g. 10 pack years = 1 pack/day x 10 years, or ½ pack/day x 20 years).
- •Patients who understand the process of clinical trial and signed written informed consent.
排除标准
- •Patients with a current diagnosis of asthma.
- •Patients with the following lung disorders that can affect the clinical trial, except for COPD: lung cancer, interstitial lung disease, thromboembolic pulmonary disease, moderate to severe bronchiectasis, sarcoidosis, pulmonary fibrosis, pulmonary hypertension, active tuberculosis, clinically significant tuberculous destroyed lung, alpha1-antitrypsin deficiency, etc.
- •Patients underwent pulmonary lobectomy or lung volume reduction surgery within the past year.
- •Patients who developed COPD exacerbation where antibiotics and/or systemic corticosteroids and/or hospitalization is advisable within 4 weeks prior to Visit 1 or during Run-in period (but, re-screening is possible 4 weeks after resolution of the COPD exacerbation occurred within 4 weeks prior to Visit 1).
- •Patients who administered antibiotics for lower respiratory infection within 4 weeks prior to Visit 1 or during Run-in period (but, re-screening is possible 4 weeks after resolution of COPD exacerbation occurred within 4 weeks prior to Visit 1).
- •Patients who have changed the COPD treatment method within 12 weeks prior to Visit 1 (but, PDE4 inhibitor can be used until 4 weeks prior to Visit 1).
- •Patients administered systemic corticosteroids within 4 weeks prior to Visit
- •Patients with the following clinically significant cardiovascular diseases: a history of myocardial infarction or unstable angina within 6 months prior to Visit 1, a history of unstable arrhythmia where its therapy method has been changed within 1 year prior to Visit 1, a history of hospitalization from NYHA Class III-IV heart failure, a history of atrial fibrillation, negative cardiac tachycardia, and/or hypertrophic cardiomyopathy.
- •Patients with a history of long QTc syndrome.
- •Patients with the clinical significance of ECG abnormality at screening (QTc(F) ≥ 470 ms).
- •Patients who require long-term oxygen therapy for more than 12 hours a day.
- •Patients participated in acute respiratory rehabilitation within 6 months prior to Visit 1 (except for the patients under stabilized respiratory rehabilitation therapy of at least 6 weeks).
研究组 & 干预措施
HCP1202
Experimental
Test
干预措施: HCP1202 (Drug)
HGP1011
Active Comparator
Control
干预措施: HGP1011 (Drug)
HCP0910
Active Comparator
Control
干预措施: HCP0910 (Drug)
结局指标
主要结局
Change from Baseline in Trough FEV1 at Week 12
时间窗: Baseline, Week 12
次要结局
- Change from Baseline in Trough FEV1/FVC at Week 4 & 8 & 12(Baseline, Week 4, Week 8, Week 12)
- Percentage (%) of Subjects Experienced with Moderate to Severe COPD Exacerbation from Baseline to Week 12(Baseline through Week 12)
- Average Daily Use of Rescue Medication per Subject from Baseline to Week 12(Baseline through Week 12)
- Change from Baseline in Total SGRQ-C (St. George's Respiratory Questionnaire for COPD patients) and sectional scores at Week 4 & 8 & 12(Baseline, Week 4, Week 8, Week 12)
- Number of Occurrences in Moderate to Severe COPD Exacerbation per Subject from Baseline to Week 12(Baseline through Week 12)
- Total Amount of Rescue Medication Used per Subject from Baseline to Week 12(Baseline through Week 12)
- Change from Baseline in Trough FVC at Week 4 & 8 & 12(Baseline, Week 4, Week 8, Week 12)
- Transition Dyspnea Index scores at Week 4 & 8 & 12(Week 4, Week 8, Week 12)
- Change from Baseline in Trough FEV1 at Week 4 & 8(Baseline, Week 4, Week 8)
研究者
相似试验
已完成
3 期
Trial to Evaluate the Efficacy and Safety of HCP1302HypertensionErectile DysfunctionNCT02587988Hanmi Pharmaceutical Company Limited232
已完成
3 期
A Study to Evaluate the Efficacy and Safety of HCP2102 in Essential Hypertension PatientsHypertensionNCT05450601Hanmi Pharmaceutical Company Limited249
已完成
3 期
A Study to Evaluate Efficacy and Safety of HCP1401 for Stage 2 Hypertension Patients Not Controlled by HCP0605HypertensionNCT02916602Hanmi Pharmaceutical Company Limited340
已完成
3 期
A Study to Evaluate Efficacy and Safety of HM11260C in Adult Obesity Patients Without Diabetes MellitusObesityNCT06174779Hanmi Pharmaceutical Company Limited448
已完成
2 期
A Phase 2 Study to Explore the Dose of HCP1803 in Patients With Essential HypertensionHypertensionNCT04959305Hanmi Pharmaceutical Company Limited245